600721 XD百花医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.8255.2155.6621.889-5.157
总资产报酬率 ROA (%)0.6063.6793.8111.257-3.505
投入资产回报率 ROIC (%)0.6864.2734.5871.551-4.287

边际利润分析
销售毛利率 (%)48.01645.52951.18849.03739.918
营业利润率 (%)10.85211.3949.6014.862-8.786
息税前利润/营业总收入 (%)10.60311.1069.1944.229-9.258
净利润/营业总收入 (%)9.88810.47810.7533.513-9.928

收益指标分析
经营活动净收益/利润总额(%)161.895176.263251.468413.100-82.173
价值变动净收益/利润总额(%)11.549-16.5229.14211.860-0.034
营业外收支净额/利润总额(%)-0.372-0.187-0.464-8.9464.282

偿债能力分析
流动比率 (X)2.3632.2911.8871.8311.749
速动比率 (X)2.2362.1681.5641.4261.232
资产负债率 (%)26.04526.94431.93833.46433.410
带息债务/全部投入资本 (%)12.30711.34214.76712.72811.984
股东权益/带息债务 (%)671.627736.745543.623642.967687.595
股东权益/负债合计 (%)283.950271.136213.107198.825199.308
利息保障倍数 (X)-50.853-41.735-25.331-18.028117.429

营运能力分析
应收账款周转天数 (天)164.25295.34845.45517.45119.092
存货周转天数 (天)77.608110.700214.662262.317294.099